Related Experiment Video
Updated: Aug 26, 2025
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
[Hematopoietic cell transplantation for FLT3-mutated acute myeloid leukemia]
1Department of Blood Transfusion, University of Fukui Hospital.
Abstract:
FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 25-30% of patients with acute myeloid leukemia (AML). Due to poor prognosis associated with FLT3-mutated AML, allogeneic hematopoietic transplantation is commonly performed to induce remission. With the availability of active FLT3 inhibitors and improvement in transplants techniques, the outcomes of AML have improved drastically. The results of many clinical trials have shown that FLT3 inhibitors in combination with chemotherapy and post-transplant maintenance therapy are most effective for AML. Furthermore, these developments have opened up the possibility of transplantation for elderly patients in whom transplantation is difficult. Here, we discuss the optimal approach for treating FLT3-mutated AML using FLT3 inhibitors, allogenic transplantation, and post-transplant maintenance therapy.
Insights
FMS-like tyrosine kinase 3 (FLT3) inhibitors combined with chemotherapy and transplantation improve outcomes for acute myeloid leukemia (AML). This approach offers new hope, even for elderly patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FMS-like tyrosine kinase 3 (FLT3) mutations occur in 25-30% of acute myeloid leukemia (AML) patients.
- FLT3-mutated AML is associated with a poor prognosis, often necessitating allogeneic hematopoietic transplantation.
- Advances in FLT3 inhibitors and transplant techniques have significantly improved AML outcomes.
Purpose of the Study:
- To discuss the optimal treatment strategy for FLT3-mutated AML.
- To highlight the role of FLT3 inhibitors, allogeneic transplantation, and post-transplant maintenance therapy.
Main Methods:
- Review of clinical trial results.
- Discussion of therapeutic combinations.
- Analysis of transplant advancements.
Main Results:
- FLT3 inhibitors combined with chemotherapy and post-transplant maintenance are highly effective for AML.
- These advancements expand transplantation eligibility to elderly patients.
- Improved outcomes are observed in FLT3-mutated AML.
Conclusions:
- Optimal treatment for FLT3-mutated AML involves a multi-modal approach.
- FLT3 inhibitors are crucial in combination therapies and post-transplant strategies.
- Therapeutic progress enables broader application of transplantation in AML management.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...